Approaching precision medicine by tailoring the microbiota

Mamm Genome. 2021 Aug;32(4):206-222. doi: 10.1007/s00335-021-09859-3. Epub 2021 Mar 1.

Abstract

Accumulating evidence has revealed the link between the microbiota and various human diseases. Advances in high-throughput sequencing technologies have identified some consistent disease-associated microbial features, leading to the emerging concept of microbiome-based therapeutics. However, it is also becoming clear that there are considerable variations in the microbiota among patients with the same disease. Variations in the microbial composition and function contribute to substantial differences in metabolic status of the host via production of a myriad of biochemically and functionally different microbial metabolites. Indeed, compelling evidence indicates that individuality of the microbiome may result in individualized responses to microbiome-based therapeutics and other interventions. Mechanistic understanding of the role of the microbiota in diseases and drug metabolism would help us to identify causal relationships and thus guide the development of microbiome-based precision or personalized medicine. In this review, we provide an overview of current efforts to use microbiome-based interventions for the treatment of diseases such as cancer, neurological disorders, and diabetes to approach precision medicine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diabetes Mellitus / genetics
  • Diabetes Mellitus / microbiology
  • Gastrointestinal Microbiome / drug effects
  • Gastrointestinal Microbiome / genetics*
  • Genome, Human / genetics*
  • Humans
  • Inactivation, Metabolic / genetics*
  • Neoplasms / genetics
  • Neoplasms / microbiology
  • Nervous System Diseases / genetics
  • Nervous System Diseases / microbiology
  • Precision Medicine*